EXPERT HIGHLIGHTS: CLINICAL TRIAL SPOTLIGHT JAVELIN 100 STUDY – PHASE 3
SIU Academy®. Faculty / Presenter(s) . 11/18/20; 313538
 Faculty / Presenter(s)
Faculty / Presenter(s)
About this activity
Recent advances in genomics and sequencing technologies have led to a more in-depth understanding of the pathogenesis of GU cancers, resulting in the discovery of new molecular targets. The development of a number of novel therapies, such as checkpoint inhibitors and other targeted therapies, has allowed for a more optimized treatment approach. In 2019 and 2020, several new drugs were approved by the U.S. Food and Drug Administration (FDA) for all stages of bladder cancer.

Faculty:

Moderator:
Tilman Todenhöfer
Clinical Trial Unit Studienpraxis Urologie
Professor of Urology
Eberhard‐Karls‐University Tübingen
Germany

Matthew Galsky
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Associate Director, Translational Research
Tisch Cancer Institute
United States

Petros Grivas
Associate Professor, Department of Medicine,
Division of Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer
Research Center
Seattle Cancer Care Alliance
United States




This educational activity is supported by Merck KGaA, Darmstadt, Germany – Pfizer Alliance



 

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies